newsfilter
← Latest News
Business Wire·

Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] announced that Ipsen, SA ("Ipsen") has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal inje